Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07230145 | A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure | PHASE1 | NOT YET_RECRUITING | 48 | — | — | Nov 1, 2025 | Jul 1, 2026 | Nov 17, 2025 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| SHR-4658 Group | EXPERIMENTAL | - |
| SHR-4658 Placebo Group | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SHR-4658 Injection. | DRUG | SHR-4658 injection. |
| SHR-4658 Placebo Injection | DRUG | SHR-4658 placebo injection. |
Inclusion Criteria: 1. Able and willing to provide a written informed consent. 2. Blood pressure as defined in the protocol. 3. Male or female，aged 18 to 55 years (inclusive). 4. Meet the weight standard. Exclusion Criteria: 1. Known history or current clinically significant disease. 2. Protocol-...